Clinical Trials Browser

Nasopharyngeal Carcinoma

NCT07618078 2026-06-03

Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC

Recruiting

900 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07405086 2026-05-22

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Phase 4 Recruiting

160 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT05941741 2026-05-11

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Phase 3 Recruiting

380 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07572864 2026-05-11

Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC

Phase 2 Recruiting

9 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06190275 2026-04-24

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

Phase NA Recruiting

32 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Phase 2 Recruiting

208 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT06472713 2025-01-13

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

Phase 2 Recruiting

32 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT05431764 2022-06-24

Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma

Phase 2 Recruiting

38 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05290194 2022-04-14

Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

Phase 2 Recruiting

28 enrolled

Head & Neck

Nasopharyngeal Carcinoma

Clinical Trials

RAIRI-NPC

Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma

Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma